SANOFI US SERVICES INC.

TRD · Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

TAX · Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21).

Literal federal measure citations: H.R.1

HCR · Health Issues

Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838), insulin price cap, VICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Literal federal measure citations: S.2296, H.R.3838, S.891

BUD · Budget/Appropriations

H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions.

Literal federal measure citations: H.R.1

MMM · Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

CPT · Copyright/Patent/Trademark

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.